Health

Lilly Breaks Ground on $6.5 Billion to Supply the Pill Boom Medicare Is Funding

Medicare's Bridge program put 700,000 seniors on GLP-1s in three months, and 70% of them landed on Lilly drugs. A $6.5 billion Houston plant is the company's hedge on a pill shift Novo currently dominates.

Vincent JiangVincent Jiangtwo-minute read
Share
Lilly breaks ground on $6.5 billion API manufacturing facility
1 / 6Slide 1 of 6
Lilly breaks ground on $6.5 billion API manufacturing facility

Lilly−2.44% — Lilly, down 2.44 percent as of its last quote broke ground on Monday on a $6.5 billion, one-million-square-foot plant at Generation Park in northeast Houston, the largest project of its kind in Texas history 123. Its main job is the active ingredient for Foundayo, the obesity pill that launched in April, months behind Novo's−2.70% — Novo's, down 2.70 percent as of its last quote 14. First product is due by 2030 1.

The payer built the demand first

Medicare's Bridge program started covering obesity drugs in July at a $50 monthly co-pay, across roughly 66 million beneficiaries 4. Since then, 700,000 seniors have started GLP-1s, and 70% are on Lilly medicines, most still on the Zepbound injection 4. One in three new pill patients takes Foundayo, a share CEO Dave Ricks says grows every week 14.

Novo owns the pill, and still got marked down

Novo's London strategy day landed the same morning. Chief executive Mike Doustdar forecast pills could take half the obesity market by 2030, above Wall Street's 14 to 40%, and pointed to more than 80% of new US oral prescriptions plus $843 million in first-half oral Wegovy sales 5. The stock still fell as much as 7%: semaglutide loses US exclusivity in 2032, and 2026 sales guidance runs flat to down 6% 6. Lilly holds about 61% of the whole market 6.

Four boxes of Novo Nordisk's Wegovy (semaglutide) injection pens in different doses stacked on a pharmacy counter
Novo Nordisk's Wegovy injection pens. Novo's oral version of semaglutide currently leads the obesity pill market that Lilly's Houston plant is built to contest.Nelson R. de Lima Filho via Wikimedia Commons

The capex is the insurance policy

Lilly has committed more than $50 billion to US manufacturing since 2020, with Houston one of 10 sites underway 12. Quarterly capex has tripled, from $0.97 billion in late 2023 to $2.93 billion in the second quarter, when revenue reached $22.97 billion, up 47.7% 7. Foundayo itself booked $98 million in its debut quarter 1. The point of the shovels is a pill boom that cannot outrun Lilly's supply.

Quarterly capex has tripled since 2023, to $2.93B

$0.5B$1B$1.5B$2B$2.5B$3BQ4 '23Q2 '24Q4 '24Q2 '25Q4 '25Q2 '26$2.93BFeb 2025: $27B, four new US sites
Data
Quarterly capex
Q3 '23$0.97B
Q4 '23$1.07B
Q1 '24$0.99B
Q2 '24$1.23B
Q3 '24$1.35B
Q4 '24$1.5B
Q1 '25$1.51B
Q2 '25$1.7B
Q3 '25$2.09B
Q4 '25$2.55B
Q1 '26$2.33B
Q2 '26$2.93B
Quarterly capital spending, US$ billions, from Eli Lilly's SEC filings via Sharadar, Q3 2023 through Q2 2026. February 2025 four-site commitment per CNBC.1,7

The multiple already assumes the win

Tuesday brought the reminder that convenience cuts both ways: Viking's VK2735 held 97% of prior weight loss on every-other-week injections, against 61% on placebo, and VKTX jumped 35% 89. Phase 3, regulators, manufacturing scale and payer access still separate that data from a genuine threat 10. Lilly trades near 40 times trailing earnings, up about 8% in 2026 against the S&P 500's 13% 11, on guided revenue of $85 to $87 billion and Ken Langone's call for $2,000 within four years 12. Next readings: Foundayo filings in more than 40 countries ahead of a 2027 global rollout 2, and Novo's pledge to build oral capacity for 10 times as many patients 6. Medicare funds the demand; the concrete is certain; the multiple is a belief.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading LLY

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    AstraZeneca commits $200 million to Tempus AI through 2031 but can walk away for the shortfall

    A five-year, $200 million renewal from AstraZeneca gives Tempus AI a revenue floor it can book, filed days before a shareholder vote on a stock-funded acquisition, but the contract lets the drugmaker quit early by paying only the shortfall.

    Health

    OpenEvidence CEO tells medical students to take paper exams as OpenAI and Anthropic give doctors AI free

    Daniel Nadler built a $15 billion company on giving doctors AI answers free. On Monday he warned the doctors still training on his tool that AI erodes the skill that makes an answer worth having.

    Health

    Molina Healthcare jumps 8% on a CMS work-rule delay; director Steven Orlando sold 702 shares at $227.33

    A CMS work-rule delay bought Molina's Medicaid book time, not margin, and insiders including director Steven Orlando sold into the strength. New buyers are paying roughly 24 times a 2027 framework that is not yet guidance and must still be earned in February.

    Health

    OpenAI prices healthcare back-office work at 8.5 cents a task, undercutting Ambience Healthcare

    OpenAI's new healthcare agents run prior-authorization work at 8.5 cents a task, and Menlo Ventures says the scribe market's new dollars are going to Microsoft and Epic. Ambience's $37,500-per-doctor receipt is now the only thing it sells that the model layer does not.

    Health

    Apple's 200,000-person health AI study runs on OpenEvidence with no disclosed price

    The 200,000-person study hands a $15 billion, ad-funded startup its first consumer channel, with no fee, equity or contract disclosed, and the closest public test of whether that free AI model is eating paid clinical reference lands in Wolters Kluwer's February results.

    Health

    Globus Medical director Tobin sold his entire stake for $3.1 million five days after a guidance cut

    James Tobin's November 10 sale left him with zero shares and zero options in Globus Medical, with no trading plan, five days after the company cut its 2026 revenue outlook by up to $130 million. The board's answer was a $500 million buyback increase.

    Subscribe to TheInference for free